Credit Suisse’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-14,568
| Closed | -$271K | – | 3055 |
|
|
2023
Q3 | $271K | Sell |
14,568
-2,036
| -12% | -$42.2K | ﹤0.01% | 2961 |
|
|
2023
Q2 | $431K | Buy |
16,604
+2,862
| +21% | +$76.6K | ﹤0.01% | 2855 |
|
|
2023
Q1 | $395K | Buy |
13,742
+2,993
| +28% | +$89.1K | ﹤0.01% | 2874 |
|
|
2022
Q4 | $318K | Sell |
10,749
-8,582
| -44% | -$244K | ﹤0.01% | 3003 |
|
|
2022
Q3 | $460K | Buy |
19,331
+66
| +0.3% | +$1.52K | ﹤0.01% | 2836 |
|
|
2022
Q2 | $430K | Sell |
19,265
-909
| -5% | -$20.3K | ﹤0.01% | 2936 |
|
|
2022
Q1 | $507K | Buy |
20,174
+2,641
| +15% | +$80.5K | ﹤0.01% | 2962 |
|
|
2021
Q4 | $628K | Sell |
17,533
-795
| -4% | -$31.8K | ﹤0.01% | 3655 |
|
|
2021
Q3 | $780K | Sell |
18,328
-1,985
| -10% | -$81.8K | ﹤0.01% | 3524 |
|
|
2021
Q2 | $880K | Buy |
20,313
+1,013
| +5% | +$43.1K | ﹤0.01% | 3484 |
|
|
2021
Q1 | $787K | Sell |
19,300
-7,192
| -27% | -$273K | ﹤0.01% | 3472 |
|
|
2020
Q4 | $1.2M | Sell |
26,492
-211
| -0.8% | -$8.01K | ﹤0.01% | 3204 |
|
|
2020
Q3 | $944K | Sell |
26,703
-5,947
| -18% | -$215K | ﹤0.01% | 2973 |
|
|
2020
Q2 | $1.23M | Buy |
32,650
+7,554
| +30% | +$249K | ﹤0.01% | 2757 |
|
|
2020
Q1 | $725K | Sell |
25,096
-962
| -4% | -$38.9K | ﹤0.01% | 2900 |
|
|
2019
Q4 | $1.35M | Buy |
26,058
+13,604
| +109% | +$790K | ﹤0.01% | 2919 |
|
|
2019
Q3 | $685K | Buy |
12,454
+3,425
| +38% | +$176K | ﹤0.01% | 3245 |
|
|
2019
Q2 | $367K | Sell |
9,029
-4,461
| -33% | -$163K | ﹤0.01% | 3580 |
|
|
2019
Q1 | $408K | Buy |
13,490
+562
| +4% | +$19.2K | ﹤0.01% | 3450 |
|
|
2018
Q4 | $434K | Buy |
12,928
+2,060
| +19% | +$74.4K | ﹤0.01% | 3330 |
|
|
2018
Q3 | $459K | Sell |
10,868
-4,639
| -30% | -$183K | ﹤0.01% | 3348 |
|
|
2018
Q2 | $496K | Sell |
15,507
-258
| -2% | -$10.6K | ﹤0.01% | 3426 |
|
|
2018
Q1 | $783K | Buy |
15,765
+3,321
| +27% | +$188K | ﹤0.01% | 3123 |
|
|
2017
Q4 | $671K | Sell |
12,444
-5,486
| -31% | -$304K | ﹤0.01% | 3265 |
|
|
2017
Q3 | $1.04M | Buy |
17,930
+11,296
| +170% | +$590K | ﹤0.01% | 3065 |
|
|
2017
Q2 | $328K | Sell |
6,634
-8,573
| -56% | -$395K | ﹤0.01% | 3409 |
|
|
2017
Q1 | $660K | Sell |
15,207
-6,108
| -29% | -$292K | ﹤0.01% | 3122 |
|
|
2016
Q4 | $1.04M | Buy |
21,315
+5,695
| +36% | +$263K | ﹤0.01% | 2988 |
|
|
2016
Q3 | $748K | Sell |
15,620
-14,916
| -49% | -$737K | ﹤0.01% | 3183 |
|
|
2016
Q2 | $1.64M | Sell |
30,536
-15,168
| -33% | -$715K | ﹤0.01% | 2500 |
|
|
2016
Q1 | $2.04M | Buy |
45,704
+21,804
| +91% | +$884K | ﹤0.01% | 2190 |
|
|
2015
Q4 | $912K | Buy |
23,900
+9,662
| +68% | +$370K | ﹤0.01% | 2888 |
|
|
2015
Q3 | $454K | Sell |
14,238
-276
| -2% | -$9.62K | ﹤0.01% | 3466 |
|
|
2015
Q2 | $480K | Buy |
14,514
+2,716
| +23% | +$96.9K | ﹤0.01% | 3756 |
|
|
2015
Q1 | $486K | Sell |
11,798
-4,709
| -29% | -$190K | ﹤0.01% | 3552 |
|
|
2014
Q4 | $672K | Sell |
16,507
-7,242
| -30% | -$283K | ﹤0.01% | 3483 |
|
|
2014
Q3 | $870K | Sell |
23,749
-13,655
| -37% | -$590K | ﹤0.01% | 3176 |
|
|
2014
Q2 | $1.73M | Sell |
37,404
-7,538
| -17% | -$335K | ﹤0.01% | 2842 |
|
|
2014
Q1 | $1.85M | Buy |
44,942
+25,182
| +127% | +$936K | ﹤0.01% | 2575 |
|
|
2013
Q4 | $754K | Buy |
19,760
+3,716
| +23% | +$115K | ﹤0.01% | 3493 |
|
|
2013
Q3 | $384K | Buy |
16,044
+1,372
| +9% | +$30.8K | ﹤0.01% | 3643 |
|
|
2013
Q2 | $249K | Buy |
+14,672
| New | +$212K | ﹤0.01% | 3743 |
|
Other funds holding ANIK
TI
CP
BFM
CM
Credit Suisse's ANIK Position: Q4 2023 in Review
Credit Suisse sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 14,568 shares — an estimated $271K sold.
Credit Suisse first reported a position in ANIK in Q2 2013 and held it in 42 quarters. The position peaked at $2.04M in Q1 2016. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.
- Credit Suisse reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 14,568 Anika Therapeutics shares in Q4 2023, an estimated $271K.
- Credit Suisse first reported a position in Anika Therapeutics in Q2 2013 and held it in 42 quarters.
- Credit Suisse's Anika Therapeutics position peaked at $2.04M in Q1 2016.
- 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.